BOLT vs. VSTM, CRIS, FBIO, SABS, MTEM, AMGN, VRTX, REGN, GILD, and BIIB
Should you be buying Bolt Biotherapeutics stock or one of its competitors? The main competitors of Bolt Biotherapeutics include Verastem (VSTM), Curis (CRIS), Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), Molecular Templates (MTEM), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Gilead Sciences (GILD), and Biogen (BIIB). These companies are all part of the "biotechnology" industry.
Verastem (NASDAQ:VSTM) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.
Verastem currently has a consensus target price of $25.69, indicating a potential upside of 655.51%. Bolt Biotherapeutics has a consensus target price of $3.50, indicating a potential upside of 359.92%. Given Bolt Biotherapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Verastem is more favorable than Bolt Biotherapeutics.
Bolt Biotherapeutics has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Verastem received 518 more outperform votes than Bolt Biotherapeutics when rated by MarketBeat users. However, 65.57% of users gave Bolt Biotherapeutics an outperform vote while only 65.28% of users gave Verastem an outperform vote.
88.4% of Verastem shares are held by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are held by institutional investors. 2.2% of Verastem shares are held by insiders. Comparatively, 30.9% of Bolt Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Verastem has a net margin of 0.00% compared to Verastem's net margin of -556.59%. Verastem's return on equity of -51.74% beat Bolt Biotherapeutics' return on equity.
Verastem has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, Bolt Biotherapeutics has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500.
In the previous week, Verastem had 2 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 3 mentions for Verastem and 1 mentions for Bolt Biotherapeutics. Bolt Biotherapeutics' average media sentiment score of 0.00 equaled Verastem'saverage media sentiment score.
Summary
Bolt Biotherapeutics beats Verastem on 9 of the 17 factors compared between the two stocks.
Get Bolt Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BOLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bolt Biotherapeutics Competitors List
Related Companies and Tools
